REGENERON PHARMACEUTICALS, INC. — Director's Dealing 2012

Nov 27, 2012

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: REGENERON PHARMACEUTICALS INC (REGN)
CIK: 0000872589
Period of Report: 2012-11-26

Reporting Person: BAKER CHARLES A (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2012-11-26	Common Stock	M	1100.0	$9.17	Acquired	10690.0	Direct
2012-11-26	Common Stock	S	1100.0	$175.14	Disposed	9590.0	Direct
2012-11-26	Common Stock	M	6565.0	$9.17	Acquired	16155.0	Direct
2012-11-26	Common Stock	S	6565.0	$174.46	Disposed	9590.0	Direct
2012-11-26	Common Stock	M	5035.0	$9.17	Acquired	14625.0	Direct
2012-11-26	Common Stock	S	5035.0	$173.63	Disposed	9590.0	Direct
2012-11-26	Common Stock	M	1200.0	$9.17	Acquired	10790.0	Direct
2012-11-26	Common Stock	S	1200.0	$172.65	Disposed	9590.0	Direct
2012-11-26	Common Stock	M	1100.0	$9.17	Acquired	10690.0	Direct
2012-11-26	Common Stock	S	1100.0	$171.45	Disposed	9590.0	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2012-11-26	Non-Qualified Stock Option (right to buy)	$9.17	M	1100.0	Disposed	2015-01-03	Common Stock (1100.0)	Direct
2012-11-26	Non-Qualified Stock Option (right to buy)	$9.17	M	6565.0	Disposed	2015-01-03	Common Stock (6565.0)	Direct
2012-11-26	Non-Qualified Stock Option (right to buy)	$9.17	M	5035.0	Disposed	2015-01-03	Common Stock (5035.0)	Direct
2012-11-26	Non-Qualified Stock Option (right to buy)	$9.17	M	1200.0	Disposed	2015-01-03	Common Stock (1200.0)	Direct
2012-11-26	Non-Qualified Stock Option (right to buy)	$9.17	M	1100.0	Disposed	2015-01-03	Common Stock (1100.0)	Direct

Footnotes

F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).

F2: Represents volume-weighted average price of sales of 1,100 shares of Company stock on November 26, 2012 at prices ranging from $175.00 to $175.55. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 26, 2012 at each separate price.

F3: Represents volume-weighted average price of sales of 6,565 shares of Company stock on November 26, 2012 at prices ranging from $174.07 to $174.91. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 26, 2012 at each separate price.

F4: Represents volume-weighted average price of sales of 5,035 shares of Company stock on November 26, 2012 at prices ranging from $173.08 to $173.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 26, 2012 at each separate price.

F5: Represents volume-weighted average price of sales of 1,200 shares of Company stock on November 26, 2012 at prices ranging from $172.06 to $172.94. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 26, 2012 at each separate price.

F6: Represents volume-weighted average price of sales of 1,100 shares of Company stock on November 26, 2012 at prices ranging from $171.01 to $171.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 26, 2012 at each separate price.

F7: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant

F8: Exercisable date, exercise date, exercise price, purchase price, sales price, and/or expiration date is/are not applicable in this case.